Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • Other: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Apr 3, 2025
  • Expires: Apr 2, 2026
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    ( Ratings)

Faculty

Tyler J.  Gluckman Tyler J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Rishi Wadhera Rishi Wadhera, MD, MPP, MPhil
Associate Professor of Medicine, Harvard Medical School
Associate Professor of Health Policy & Management, Harvard School of Public Health
Division of Cardiology
Beth Israel Deaconess Medical Center & Harvard Medical School
Boston, Massachusetts

Needs Statement

Healthcare providers are unfamiliar with LDL-C targets and how to implement therapeutic regimens to achieve treatment goals in rural patient populations. 

Healthcare providers lack familiarity with the role of elevated Lp(a) as a risk factor for ASCVD and how to target elevated Lp(a) in rural settings.

Healthcare providers in rural communities struggle to effectively collaborate with both patients and academic centers to implement tactics that allow patients living in rural and/or underserved areas improved access to healthcare.

Target Audience

The target audience for this course includes physicians, advance practice providers, and pharmacists.

Objectives

Upon completion of this activity, participants will be able to:
1. Review characteristics of novel nonstatin medications that can be used to achieve LDL-C targets.
2. Discuss the current and emerging role of lipoprotein(a) assessment.
3. Describe barriers to equitable care for individuals living in rural communities.

Accreditation

In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and Partners for Advancing Clinical Education. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CPE
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Ty Gluckman, MD, faculty for this educational event, is a consultant for OptumRx.

Rishi Wadhera, MD, faculty for this educational event, is a current consultant with Abbott Vascular and a former consultant with Chambercardio.

All of the relevant financial relationships listed for these individuals have been mitigated. No other speakers, authors, planners or content reviewers have any relevant financial relationship to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Partners for Advancing Clinical Education.

Supported by an unrestricted educational grant from Novartis.

Special Services

If you require special assistance to attend this event, please contact jodie.weber@uky.edu.

The University of Kentucky is an equal-opportunity university.